Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma

BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) and survivin have been identified as potential targets for cancer vaccination. In this phase II study a vaccine using the peptides Sur1M2 and IDO5 was combined with the chemotherapy temozolomide (TMZ) for treatment of metastatic melanoma patients. The ai...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Stem Cell Investig
Autors principals: Nitschke, Nikolaj Juul, Bjoern, Jon, Iversen, Trine Zeeberg, Andersen, Mads Hald, Svane, Inge Marie
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2017
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5639040/
https://ncbi.nlm.nih.gov/pubmed/29057249
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/sci.2017.08.06
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars